Vericel Corporation (NASDAQ:VCEL)’s Stock Is Sell After More Market Selling

June 13, 2018 - By reb123z

Vericel Corporation (NASDAQ:VCEL) Logo

The stock of Vericel Corporation (NASDAQ:VCEL) registered an increase of 15.54% in short interest. VCEL’s total short interest was 1.51 million shares in June as published by FINRA. Its up 15.54% from 1.30 million shares, reported previously. With 738,700 shares average volume, it will take short sellers 2 days to cover their VCEL’s short positions. The short interest to Vericel Corporation’s float is 5.3%.

The stock decreased 2.26% or $0.3 during the last trading session, reaching $12.95. About 646,258 shares traded. Vericel Corporation (NASDAQ:VCEL) has risen 389.29% since June 13, 2017 and is uptrending. It has outperformed by 376.72% the S&P500.

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, makes, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company has market cap of $549.49 million. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. It currently has negative earnings. The firm also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.

Vericel Corporation (NASDAQ:VCEL) Ratings Coverage

Among 4 analysts covering Vericel Corp (NASDAQ:VCEL), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vericel Corp had 6 analyst reports since January 2, 2018 according to SRatingsIntel. The rating was maintained by BTIG Research with “Buy” on Thursday, April 12. BTIG Research maintained it with “Buy” rating and $1300 target in Wednesday, March 28 report. As per Monday, March 5, the company rating was maintained by BTIG Research. The rating was initiated by Leerink Swann with “Buy” on Wednesday, April 4. The rating was maintained by Piper Jaffray on Tuesday, January 2 with “Buy”.

More notable recent Vericel Corporation (NASDAQ:VCEL) news were published by: Streetinsider.com which released: “After-Hours Stock Movers 05/30: (TLYS) (KEYS) (VSI) Higher; (CRSP) (VCEL) (BOX) Lower (more…)” on May 30, 2018, also Seekingalpha.com with their article: “Vericel Q1 Results: Full Speed Ahead” published on May 27, 2018, Globenewswire.com published: “Vericel to Present at the Jefferies 2018 Global Healthcare Conference” on May 25, 2018. More interesting news about Vericel Corporation (NASDAQ:VCEL) were released by: Nasdaq.com and their article: “Vericel Corporation Announces Closing of $74.8 Million Public Offering and Full Exercise of The Underwriters’ Option …” published on June 05, 2018 as well as Globenewswire.com‘s news article titled: “Vericel Corporation Announces Proposed Public Offering of Common Stock” with publication date: May 30, 2018.

Vericel Corporation (NASDAQ:VCEL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: